Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OptimizeRx Corp Director's Dealing 2019

Feb 26, 2019

33090_dirs_2019-02-26_16a10e92-2ed6-4928-9c39-cf51fad35244.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2019-02-25

Reporting Person: FEBBO WILLIAM J (Director, CHIEF EXECUTIVE OFFICER)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-02-25 Option $1.07 J 100000 Acquired 2021-02-28 Common Stock (100000) Direct
2019-02-25 Restricted Stock Grant $ A 30000 Acquired Common Stock (30000) Direct

Footnotes

F1: Not applicable.

F2: The Issuer and the Reporting Person amended the Reporting Person's employment agreement to vest his options as of February 28, 2019.

F3: Each restricted stock grant represents a contingent right to receive one share of the Issuer's common stock.

F4: The reporting person received a restricted stock grant that may vest on February 1, 2020, subject to achievement of the Issuer's year-end revenue performance goals.